Convalescent Plasma the Experience and Journey from Blockbuster to Incognito: A Single Centre Experience

Convalescent Plasma the Experience and Journey from Blockbuster to Incognito: A Single Centre Experience

Convalescent plasma has been used to provide passive immunotherapy to patients with COVID-19 with a high level of safety. Very few efficacy studies were available, and due to COVID being a relatively new disease, its exact therapeutic role was unclear. This observational study on the impact of COVID...

Full description

Saved in:
Bibliographic Details
Published in:Recent advances in anti-infective drug discovery Vol. 18; no. 3; p. 188
Main Authors: Negi, Gita, Kaur, Daljit, Jain, Ashish, Mohan, Yatendra Kumar, Meinia, Sushant Kumar, Kaur, Pandeep, Panda, Prasan Kumar, Kalita, Deepjyoti, Ravikant
Format: Journal Article
Language:English
Published: United Arab Emirates 2023
Subjects:
Adult
Aged
Aged, 80 and over
Blood Donors
COVID-19 - therapy
COVID-19 Serotherapy
Female
Humans
Immunoglobulin G
Male
Middle Aged
SARS-CoV-2
Young Adult
COVID-19
Convalescent plasma
recovery
immunoglobulin
pandemic
efficacy
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Convalescent plasma has been used to provide passive immunotherapy to patients with COVID-19 with a high level of safety. Very few efficacy studies were available, and due to COVID being a relatively new disease, its exact therapeutic role was unclear. This observational study on the impact of COVID convalescent plasma (CCP) on clinical outcomes attempts to evaluate the effectiveness of convalescent COVID-19 plasma therapy in the treatment of COVID-19 patients at the tertiary care center in the Uttarakhand state of India. CCP was collected by plasmapheresis/whole blood from willing COVIDrecovered donors who underwent pre-donation testing including ABO and RhD grouping, mandatory blood screening tests for HIV, HBV, HCV, syphilis and Malaria, Haemoglobin estimation and COVID IgG assay. Hospitalized patients with severe COVID-19 pneumonia who received these CCP units were followed up and the outcome (Recovery/death) was observed. A total of 63 patients who received CCP were included in the study. Out of the total, 13 (20.7%) were females and 50 (79.3%) were males and their ages ranged from 24 to 80 years with a median age of 53 years. The period between the start of symptoms and hospitalization ranged from 1 to 14 days with an average duration of 4.7 days. Symptoms on presentation included Fever 53/63 (84.1%), Tachypnoea 60/63 (95.2%) and Cough 42/63 (66.7%). Among these patients, 22/63 (34.9%) were on non-invasive ventilation (NIV), 6/63 (9.5%) on non-rebreather mask (NRBM) and 32/63 (50.8%) were on Ventilator support. The infused convalescent plasma had a Mean IgG value of 57.3 AU with a range of (10-142 AU). A total of 37 (58.7%) patients were lost to COVID-19 infection and 26 (41.3%) were discharged from the hospital in a healthy state. The use of convalescent plasma in addition to standard treatment in our study on patients with severe pneumonia due to COVID-19 did not demonstrate reduced mortality of COVID-19 patients amidst numerous variables. The results showed that the use of convalescent plasma as a treatment option in the present conditions needs a serious re-evaluation. Studies on a strictly defined recipient group and transfusion of CCP units, with adequate antibody titer and/or neutralization activity, must be analyzed for future works.
ISSN:2772-4352
DOI:10.2174/2772434417666220622140416